MedPath
FDA Approval

Brimonidine Tartrate

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Apotex Corp.
DUNS: 845263701
Effective Date
December 13, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Brimonidine(1.5 mg in 1 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Apotex Inc.

209429182

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Apotex Inc.

Apotex Corp.

Apotex Inc.

255092496

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Brimonidine Tartrate

Product Details

NDC Product Code
60505-0564
Application Number
ANDA078479
Marketing Category
ANDA (C73584)
Route of Administration
OPHTHALMIC
Effective Date
December 13, 2023
Code: 4S9CL2DY2HClass: ACTIBQuantity: 1.5 mg in 1 mL
boric acidInactive
Code: R57ZHV85D4Class: IACT
calcium chlorideInactive
Code: M4I0D6VV5MClass: IACT
magnesium chlorideInactive
Code: 02F3473H9OClass: IACT
potassium chlorideInactive
Code: 660YQ98I10Class: IACT
sodium borateInactive
Code: 91MBZ8H3QOClass: IACT
waterInactive
Code: 059QF0KO0RClass: IACT
CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIEDInactive
Code: K679OBS311Class: IACT
sodium chlorideInactive
Code: 451W47IQ8XClass: IACT
hydrochloric acidInactive
Code: QTT17582CBClass: IACT
sodium hydroxideInactive
Code: 55X04QC32IClass: IACT
sodium chloriteInactive
Code: G538EBV4VFClass: IACT
© Copyright 2025. All Rights Reserved by MedPath